Damora Therapeutics, Inc.
Damora Therapeutics, Inc.
- Market cap
- $1.44B
Your view on DMRA
Overview
What the company does, where it operates, and who runs it.
About Damora Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jennifer A. Jarrett
- Headquarters
- Building 23, Waltham, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jennifer A. Jarrett
- Headquarters
- Building 23, Waltham, MA, US
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2.
Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Damora Therapeutics, Inc.. Starting points for Damora Therapeutics, Inc.: EPS -$4.72, beta 1.51 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Damora Therapeutics, Inc.. Trailing twelve-month EPS for Damora Therapeutics, Inc. stands at -$4.72. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Damora Therapeutics, Inc.. Damora Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NTRBNutriband Inc. | Healthcare | NASDAQ | $59.8M | ||
| NTRBWNutriband Inc. | Healthcare | NASDAQ | $76.8M | ||
| NTRRNeutra Corp. | Healthcare | OTC | $291,790 | ||
| NURPFNeuren Pharmaceuticals Limited | Healthcare | OTC | $1.1B | ||
| NUVBNuvation Bio Inc. | Healthcare | NYSE | $1.3B | ||
| NUZ.AXNeurizon Therapeutics Limited | Healthcare | ASX | — | ||
| NVAXNovavax, Inc. | Healthcare | NASDAQ | $1.2B | ||
| NVCTNuvectis Pharma, Inc. | Healthcare | NASDAQ | $666.8M | ||
| NWBONorthwest Biotherapeutics, Inc. | Healthcare | OTC | $359.4M | ||
| NWPHFNewron Pharmaceuticals S.p.A. | Healthcare | OTC | $239.5M | ||
| NXTCNextCure, Inc. | Healthcare | NASDAQ | $29.5M | ||
| NYMXFNymox Pharmaceutical Corporation | Healthcare | OTC | $4.8M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Damora Therapeutics, Inc., and how their positions are changing. At a $1.44B market value, institutional positions materially move Damora Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Damora Therapeutics, Inc. executives and directors. Shares of Damora Therapeutics, Inc. have traded between $2.45 and $38.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Damora Therapeutics, Inc.. Coverage tracks Damora Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Damora Therapeutics, Inc.